Source page: McKinsey & Company
Commentary
A boon for biotech
Biotech | Start-ups | Venture capital
September 12, 2022 – Biotech start-ups with next-generation platform technologies—such as new therapeutic delivery methods and machine-learning-enabled drug discovery—have captured the lion’s share of recent venture-capital (VC) investment in the industry. Start-ups with these technologies attracted nearly $35 billion in VC funding from 2019 to 2021, compared with $17 billion for other therapeutics such as immunology.
To read the article, see “What are the biotech investment themes that will shape the industry?,” June 10, 2022.
customizer here
Visual form
Treemap.
Layout / body structure
A single treemap fills the visual area. Reader starts with the two big category blocks, then reads the individual rectangles inside each block from the largest areas to the smaller subsegments.
What is being compared
The chart compares seed-to-series C venture-capital funding in privately held biotech companies from 2019 to 2021, split between platform-based therapeutics and other therapeutics, and then broken down into the individual technology or disease-area segments inside each group.
Measurement system
The values are shown in billions of dollars. Rectangle size represents the amount of VC funding allocated to each segment, and the side labels give the category totals.
Visible structure inside the graphic
The treemap has two large fields: a blue platform-based therapeutics block totaling 34.6 and a gray other therapeutics block totaling 17.2. Inside the platform block, the largest rectangles are cell therapy 2.0 at 7.7 and next-generation gene therapies at 7.6, followed by precision medicine at 4.5, machine-learning-enabled drug discovery at 4.4, validated but undruggable targets at 4.0, new delivery methods at 2.3, other biologics at 3.4, and small molecules at 0.8. Inside the other therapeutics block, the largest rectangles are immuno-oncology at 4.6, neurological disorders at 2.9, infectious diseases at 2.5, other oncology at 2.4, other at 2.1, immunology at 0.9, metabolic diseases at 0.8, cardiovascular at 0.6, and aging at 0.5.
Main takeaway from the visual
The visual shows venture capital concentrating much more heavily in platform-based therapeutics than in the rest of biotech, and within that platform block the biggest money clusters around cell therapy 2.0 and next-generation gene therapies.
Key standout values or extremes
Platform-based therapeutics take 34.6 billion dollars versus 17.2 billion for other therapeutics. The two biggest individual segments are cell therapy 2.0 at 7.7 and next-generation gene therapies at 7.6, while the smallest labeled segments are aging at 0.5, cardiovascular at 0.6, and small molecules at 0.8.
Controls / sequence, when applicable
This is a static chart image with no in-chart controls to operate.
Companion media, when applicable
There is no separate companion audio or video; the chart image is the full visual on this page.